Originally posted by C0|dB|00ded
View Post
Because of limited sequenced virus, Delta-specific VE was not assessed.
The efficacy against severe disease dropped 3% from 87% to 84% over that six week period. There simply isn't enough data to know if it continued to decline as delta continued to ramp up and now overwhelms the result.
We are being told the J&J study is specifically against a delta environment, but that may be B.S. or it may be spot on -- won't know 'til it's published.
71% may trump both Moderna and Pfizer in a pure delta environment. Or it may fall well short. There's just not enough data to know yet.
Comment